Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

PURPOSE: The CAPTIVATE study investigated first-line ibrutinib plus venetoclax for chronic lymphocytic leukemia in 2 cohorts: minimal residual disease (MRD)-guided randomized discontinuation (MRD cohort) and Fixed Duration (FD cohort). We report outcomes of fixed-duration ibrutinib plus venetoclax i...

Descripción completa

Detalles Bibliográficos
Autores principales: Allan, John N., Flinn, Ian W., Siddiqi, Tanya, Ghia, Paolo, Tam, Constantine S., Kipps, Thomas J., Barr, Paul M., Elinder Camburn, Anna, Tedeschi, Alessandra, Badoux, Xavier C., Jacobs, Ryan, Kuss, Bryone J., Trentin, Livio, Zhou, Cathy, Szoke, Anita, Abbazio, Christopher, Wierda, William G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345960/
https://www.ncbi.nlm.nih.gov/pubmed/37282671
http://dx.doi.org/10.1158/1078-0432.CCR-22-2779

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345960/
https://www.ncbi.nlm.nih.gov/pubmed/37282671
http://dx.doi.org/10.1158/1078-0432.CCR-22-2779

Ejemplares similares